• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Serum neurofilament light chain elevations may be viable as a biomarker for multiple sclerorsis

byPaary BalakumarandAlex Chan
May 23, 2024
in Chronic Disease, Imaging and Intervention, Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Serum neurofilament light chain (sNfL) elevations are a relatively specific biomarker of magnetic resonance imaging (MRI) disease activity in multiple sclerosis (MS) (82%–91.9% specificity) but have a low sensitivity (27.9%–42.6% sensitive)

2. Peak increase in sNfL was observed at an average of 9 weeks after the first Gd+ lesion was seen and remained high after resolution of Gd+ lesions in many participants. 

Evidence Rating Level: 1 (Excellent) 

Magnetic resonance imaging (MRIs) have been validated and included in the international guidelines for use as a prognostic marker in multiple sclerosis (MS). Due to the cost of MRI, a blood-based biomarker for inflammatory activity is needed to monitor disease progression and guide treatment. Neurofilament is a component of neuron cytoskeleton and serum neurofilament light chain (sNfL) levels correlate with disease activity, may predict prognosis, and are reduced by treatments. However, the interpretation of sNfL is currently limited by a lack of understanding of the temporal relationship between sNfL levels and disease activity. Researchers sought to further assess this in this post-hoc analysis of the RESTORE randomized trial, by comparing patients undergoing interruption natalizumab therapy and those that remained on the therapy for 24 weeks. Monthly serum and MRIs were taken to correlate MRI disease activity (i.e., gadolinium-enhancing lesions) and serum biomarkers. Compared to those without gadolinium-enhancing lesions (Gd+ lesions), participants with Gd+ lesions had significantly higher sNfL mean levels at 28 weeks (20.0 ± 30.5 vs 10.2 ± 7.9 pg/mL; p = 0.004). From baseline to week 28, participants who developed Gd+ lesions had a mean ± SD percentage increase in sNfL of 126.6% ± 232.2% vs 8.9% ± 46.2% (p < 0.001) in the participants who did not develop Gd+ lesions. There was also an increase in baseline and peak sNfL as the number of Gd+ lesions increased. In 80% of participants, new Gd+ lesions appeared before any increases in sNfL levels whereas 20% of patients reached peak sNfL levels before new Gd+ lesions were identified. Peak sNfL was delayed by an average of 8.7 ± 14.4 weeks after the first Gd+ lesion identification. Most patients with Gd+ lesions did not have elevations in sNfL levels. Using the 95th percentile sNfL levels of participants without Gd+ lesions as a threshold, sNfL was determined to be a relatively specific biomarker of MRI disease activity in MS (82%–91.9% specificity) but had low sensitivity (27.9%–42.6% sensitive). Further research into this domain may provide more insight into the possible role of sNfL as a prognostic biomarker for MS. 

Click to read the study in Neurology

Image: PD

RELATED REPORTS

Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients

2 Minute Medicine Rewind June 16, 2025

Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc. 

Tags: mrimsmultiple sclerosisneurologyradiology
Previous Post

Ticagrelor monotherapy reduces bleeding risk following percutaneous coronary intervention

Next Post

Lixisenatide as a treatment for early Parkinson’s disease progression

RelatedReports

Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults
Neurology

Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients

June 20, 2025
Survival greater in cervical cancer patients undergoing abdominal hysterectomy compared to minimally invasive techniques: the LACC trial
Weekly Rewinds

2 Minute Medicine Rewind June 16, 2025

June 16, 2025
Quick Take: The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomized trial
Chronic Disease

Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis

June 12, 2025
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Chronic Disease

Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

June 4, 2025
Next Post
Brain lesions on MRI linked with subsequent increased stroke risk

Lixisenatide as a treatment for early Parkinson’s disease progression

Pediatric DKA associated with recent acute care visits

Podiatric care for diabetic patients is associated with reduced risk of major amputation and death

Significant number of wrong-patient errors in radiology reports

Chest radiograph deep-learning model for cardiac event risk estimation

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients
  • Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms
  • #VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.